Raloxifene's Effect on Breast Cancer
Author Information
Author(s): Torrisi R, Baglietto L, Johansson H, Veronesi G, Bonanni B, Guerrieri-Gonzaga A, Ballardini B, Decensi A
Primary Institution: European Institute of Oncology
Hypothesis
Does raloxifene affect the IGF system in postmenopausal women with breast cancer?
Conclusion
Raloxifene significantly decreased IGF-I levels in postmenopausal women with breast cancer, suggesting its potential role in breast cancer prevention.
Supporting Evidence
- Raloxifene significantly decreased IGF-I levels compared to placebo.
- No significant change was observed in IGFBP-3 levels.
- The IGF-I/IGFBP-3 molar ratio was decreased by treatment.
Takeaway
Raloxifene, a medication, can lower a certain growth factor in women with breast cancer, which might help prevent the disease.
Methodology
The study investigated the effects of 60 mg and 600 mg daily doses of raloxifene administered for 2 weeks prior to surgery.
Participant Demographics
Postmenopausal women with breast cancer.
Statistical Information
P-Value
< 0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website